Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Kiyotaka Yoh's publication output changed over time?
ScholarIQpublication output · 2004–2024
Output grew0% over the shown period — from 1 works in 2004 to 1 in 2024.
1
1
2
2
1
2
1
1
20042014201520162017201920232024
What are the most-cited papers on Kiyotaka Yoh?
ScholarIQmost cited works
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Luis Paz‐Ares, Chao‐Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal, Fumio Imamura, Kiyotaka Yoh, Jin‐Yuan Shih, Kwok Hung Au, Denis Moro‐Sibilot, Sotaro Enatsu, Annamaria H. Zimmermann, Bente Frimodt‐Moller, Carla Visseren‐Grul, Martin Reck, Quincy S. Chu, Alexis B. Cortot, Jean-Louis Pujol, Denis Moro‐Sibilot, Elizabeth Fabre, Corinne Lamour, Helge Bischoff, Jens Kollmeier, Martin Reck, Martin Kimmich, Walburga Engel-Riedel, Stefan Hammerschmidt, Wolfgang Schütte, Konstantinos Syrigos, Jcm Ho, Kwok‐Hung Au, Silvia Novello, Andrea Ardizzoni, Giulia Pasello, Vanessa Gregorc, Alessandro Del Conte, Domenico Galetta, Toshiaki Takahashi, Kazuhiko Nakagawa, Makoto Nishio, Kiyotaka Yoh, Takashi Seto, Fumio Imamura, Toru Kumagai, Katsuyuki Hotta, Yasushi Goto, Yukio Hosomi, Hiroshi Sakai, Yuichi Takiguchi, Young Hak Kim, Takayasu Kurata, Hiroyuki Yamaguchi, Haruko Daga, Isamu Okamoto, Miyako Satouchi, Satoshi Ikeda, Kazuo Kasahara, Shinji Atagi, Koichi Azuma, Toru Kumagai, Keisuke Aoe, Toru Kumagai, Keisuke Aoe, Yoshitsugu Horio, Nobuyuki Yamamoto, Hiroshi Tanaka, Satoshi Watanabe, Naoyuki Nogami, Tomohiro Ozaki, Ryo Koyama, Tomonori Hirashima, Hiroyasu Kaneda, Keisuke Tomii, Yuka Fujita, Masahiro Seike, Naoki Nishimura, Terufumi Kato, Masao Ichiki, Hideo Saka, Katsuya Hirano, Yasuharu Nakahara, Shunichi Sugawara, Keunchil Park, Sang‐We Kim, Young Joo Min, Hyun Woo Lee, Jin‐Hyoung Kang, Ho Jung An, Ki Hyeong Lee, Jin-Soo Kim, Gyeong‐Won Lee, Sung Yong Lee, Aurelia Alexandru, Anghel Adrian Udrea, Óscar Juan
The Lancet Oncology. 2019616 CitationsOPEN ACCESS
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim, Suresh S. Ramalingam, Lecia V. Sequist, Wu‐Chou Su, Sang-We Kim, Joo-Hang Kim, David Planchard, Enriqueta Felip, Fiona Blackhall, Daniel Haggstrom, Kiyotaka Yoh, Silvia Novello, Kathryn A. Gold, Tomonori Hirashima, Chia‐Chi Lin, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Pasi A. Jänne
Journal of Clinical Oncology. 2017577 CitationsOPEN ACCESS
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa, Sang-We Kim, Jin-Ji Yang, Myung‐Ju Ahn, Jie Wang, James Chih‐Hsin Yang, You Lü, Shinji Atagi, Santiago Ponce, Ki Hyeong Lee, Yunpeng Liu, Kiyotaka Yoh, Jianying Zhou, Xiaojin Shi, Alan Webster, Haiyi Jiang, Tony Mok
The Lancet Oncology. 2015412 Citations
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta, Katsuya Tsuchihara, Genichiro Ishii, Shogo Nomura, Akihiro Sato, Atsushi Ohtsu, Yuichiro Ohe, Kōichi Goto
The Lancet Respiratory Medicine. 2016297 Citations
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Kōichi Goto
PubMed. 2015271 CitationsOPEN ACCESS
Related on ScholarIQ
National Cancer Center Hospital East
Institution
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Paper
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Paper
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Paper
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Paper
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Paper